http://www.craneware.com/

Craneware, Inc. is a leading supplier of business intelligence and revenue cycle software that provides clients with chargemaster management software and products designed to optimize legitimate reimbursements and assist in managing the revenue cycle through better information, workflow, pricing strategy, capture of lost revenue and best practice modeling. Our innovative and scalable products are designed to ensure that you have the information you need to succeed in healthcare financial management.

A talented mix of employees from the healthcare industry, software engineering, business consulting, customer support and training provide the perfect blend for providing extremely powerful solutions to problems faced by hospital's financial teams.

Our consultant's years of experience in the healthcare industry are the vital source of financial, clinical and coding expertise that together with talented software developers combine to make our products so effective.

Our dedicated support team work hard at ensuring our customers always come first and pride themselves on exemplary service throughout the relationship from first install to advanced user training. Installation times are in weeks instead of months, Support responses are in minutes instead of days.

Headquartered in Scotland with offices across the US, Craneware delivers unparalleled solutions to the problems facing healthcare financial managers every day.

8 Sep Panmure Gordon 654.00 Hold
8 Sep Investec 750.00 Buy

Craneware PLC (CRW.GB:ISD) set a new 52-week high during today's trading session when it reached 779.00. Over this period, the share price is up 52.40%.

AGM Statement
RNS
RNS Number : 9153F
Craneware plc
17 November 2015



Craneware plc

("Craneware" or the "Company")



AGM Statement



17 November 2015 - Craneware plc (AIM: CRW.L), the leader in Value Cycle solutions for the US healthcare market, will be holding its Annual General Meeting today at 9am. At the meeting, Keith Neilson, CEO of the Company, will make the following statement:



"We have experienced a positive start to trading in the first few months of the year. In June, we launched the Value Cycle, our vision for the process and culture by which healthcare providers pursue quality patient outcomes and optimal financial performance within a healthcare market moving towards value-based care. Our leadership in this area has further strengthened Craneware's position as a trusted partner for US healthcare organisations as they look to solve the challenges of the new value based reimbursement models.



This positive impact of the Value Cycle on the level of sales activity combined with the contribution of the prior year's sales flowing through to the current year financial results and the continued high levels of cash generation, mean we are well positioned to continue to execute on our growth strategy."



Craneware will be hosting an analyst and investor presentation at 11am today. The presentation to be given at the meeting will cover topics including the evolution of the US healthcare market towards value-based care, the escalation of patient engagement and consumerism, and the Value Cycle. The presentation will contain no new material information.



Copies of the presentation will be made available on the Company's website at www.craneware.com.

Ex dividend 19 Nov 2015 Craneware PLC (7.7 P)

11 Jan Peel Hunt 920.00 Buy

Trading Update
RNS
RNS Number : 6501M
Craneware plc
22 January 2016

Craneware plc

("Craneware", "the Group" or the "Company")



Trading Update



22 January 2016 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, provides an update on trading for the six months ended 31 December 2015.



The Group is pleased to announce it has continued to perform strongly in the first half of the financial year. Ongoing sales success has delivered an increase of 15% in the value of 'new sales' contracts signed in the six month period ended 31 December 2015 compared to the same period last year and renewals by dollar value in the period have continued at over 100%. In accordance with the Company's revenue recognition policy the majority of revenue resulting from these sales will be recognised over future periods, adding to the Group's long term visibility of revenue under contract.



As a result, the Group expects to report an increase of over 10% in adjusted EBITDA for the six months ended 31 December 2015 and a 7% increase in recognised revenue, compared with the same period last year.



High levels of cash generation in the period have resulted in cash reserves of $45m (H115:$41.8m). In addition, the Group has secured a funding facility from the Bank of Scotland of up to $50m. This will be available to the Group as it continues to investigate strategic opportunities to further expand its Value Cycle solution.



With growth in the period in line with management's expectations, high levels of cash generation and the continued sales momentum, the Board is confident in meeting market expectations for the full year.



The Company will announce results for the six months ended 31 December 2015 on 8 March 2016.



Keith Neilson, CEO of Craneware plc commented, "We are seeing the initial success of the 'Value Cycle', our vision for the process and culture by which US healthcare providers pursue quality patient outcomes and optimal financial performance, in our continued strong sales performance.



The Group's strong financial position allows us to evaluate our options as we look to enhance and add solutions which support our customers in the new Value-based reimbursement environment.



These factors combined with revenue recognition from contracted sales made in prior periods, gives management confidence in its ability to deliver increasing stakeholder value through this year and in the future

22 Jan Investec 915.00 Buy
22 Jan Peel Hunt 920.00 Buy

Significant Contract Win and Reseller Agreement
RNS
RNS Number : 7165N
Craneware plc
02 February 2016

Craneware plc

("Craneware", "the Group" or the "Company")



Significant Contract Win and Reseller Agreement



2 February 2016 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, is pleased to announce a significant new contract with a hospital operator in the US. The Company is also pleased to announce the signing of an exclusive value added reseller agreement with US-based automated payment technologies and services company, VestaCare. The Company will combine VestaCare's proprietary technology with its own to offer accelerated payment and patient engagement solutions.



Contract win

The contract is expected to deliver $7.5m revenue over the initial five year term. The new customer is a growing hospital operator and consolidator that manages in excess of 50 hospitals across multiple US states primarily in non-urban communities. Under the terms of the contract, Craneware will deliver its Chargemaster Corporate Toolkit® to establish and manage corporate standardisation across its entire portfolio of owned and managed facilities. This will enable system wide reporting efficiencies and the timely submission of accurate claims whilst managing billing compliance risk.



The Company's revenue recognition policy means that the full impact of the revenue generated from this contract will be seen from FY17 onwards.



Reseller agreement

Under the new reseller agreement, VestaCare's VestaPay technology will be integrated with Craneware's medical necessity and price estimation products, to deliver enhanced Patient Engagement solutions, a key element of Craneware's product roadmap. These will be delivered via Craneware's mobile patient engagement platform, which has been developed following the acquisition of Kestros in 2014. The enhanced solutions will help providers better address the financial risks associated with the rapidly changing role of patient financial responsibility in the era of the Value Cycle. By integrating with providers' financial systems to adjust patients' outstanding balances on their accounts in real time, providers can offer the individual a compassionate, flexible program of repayments to address patient responsibility, dramatically reducing the hospitals' exposure to "self-pay" debt. In addition, providers benefit from improved patient satisfaction, better pricing transparency and accelerated revenue. Craneware will receive an annual license fee from customers with an additional revenue share agreement based on patient collection improvements.



Keith Neilson, CEO of Craneware plc, commented, "Both of these agreements not only provide Craneware with significant future revenue opportunities but also further enhance the Company's strategic value to customers. We are delighted to sign a significant new customer, which is testament to our position as a trusted partner for US healthcare organisations. The new reseller agreement deepens our reach within the early stages of patient engagement and demonstrates our leadership in the evolving market of value-based care and patient responsibility."

Half yearly report

Financial Highlights (US dollars)



· Value of 'new sales' contracts signed in the period increased 15% compared to H1 2015

· Revenue increased 7% to $23.1m (H1 2015: $21.6m)

· Adjusted EBITDA1 increased 12% to $7.1m (H1 2015: $6.3m)

· Profit before tax increased 15% to $6.1m (H1 2015: $5.3m)

· Adjusted basic EPS increased 14% to 18.8 cents per share (H1 2015: 16.5 cents per share)

· Cash at period end increased 24% to $45m (H1 2015: $36.4m)

· Proposed interim dividend increased 19% to 7.5p (H1 2015: 6.3p per share)



1. Adjusted EBITDA refers to earnings before interest, tax, depreciation, amortisation, share based payments and acquisition and share transaction related costs.



Operational Highlights



· Continued sales momentum and record pipeline

· Positive industry response to the Value Cycle

· Chargemaster Toolkit named Best in Klas for the 10th consecutive year in "2016 Best in KLAS Awards"

· Pharmacy ChargeLink, now selling 1:1 with Chargemaster Toolkit

· Progress on delivering Trisus product roadmap:

o Development of Patient Engagement and Access gateway product on track

o Reseller agreement signed post half-year end with US based VestaCare, an automated payment technologies and services company to offer accelerated payment and patient engagement solutions

· $7.5m contract win signed post half year end with an operator of 50 US hospitals

8 Mar Peel Hunt 920.00 Buy

Dividend Currency Election
RNS
RNS Number : 5736S
Craneware plc
18 March 2016



Craneware plc

("Craneware" or the "Company")



Dividend Currency Election



18 March 2016 - Craneware plc (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, today gives further information regarding its interim dividend announced on 8 March 2016.



For those shareholders who have previously registered to receive their dividend in US dollars under the Company's Dividend Currency Election, the dividend will be paid at an exchange rate of $1.42/ £1.

28 Apr Peel Hunt 920.00 Buy

Trading Update, Contract Win and Notice of Results

RNS


RNS Number : 3413D

Craneware plc

06 July 2016




Craneware plc

("Craneware", "the Group" or the "Company")



Trading Update, Significant Contract win and Notice of Results



6 July 2016 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, provides an update on trading for the year ended 30 June 2016.



The Board is pleased to confirm the Group's third consecutive year of record sales performance and a return to double digit growth at the revenue and adjusted EBITDA level.



The Group has seen greater than 60% growth in the value of 'New Sales' contracts signed of c$58m (2015 $35.9m) with the average new contract length being maintained at 5 years.



Included in the year's sales success are two significant contracts. The first announced on 2 February 2016 was for a 50 hospital group in excess of $7.5m revenue over its five year life. In addition to this the Company is pleased to announce that it finished the year with a further multi-hospital group contract win. Starting in FY17, the contract is expected to deliver revenue greater than $8m during the next five years, as the hospital network rolls out multiple Craneware core value cycle solutions.



In accordance with the Company's revenue recognition policy, the majority of the revenue resulting from all sales will be recognised over future periods, adding to the Group's long term visibility of revenue under contract. Accordingly the Group expects to report an increase of 11% in revenues and 10% in adjusted EBITDA for the year ended 30 June 2016.



Other key performance indicators continue to be positive. The Group continued to renew hospitals that were due for renewal in the year at an average of above 100% (by $ value) and customer retention continues to be significantly higher than the industry norm.



Strong cash generation resulted in cash reserves in excess of $47m at 30 June 2016 (2015 $41.8m).



Keith Neilson, CEO of Craneware plc commented, "US Healthcare providers continue to address the challenges the new value based re-imbursement environment brings. We believe our continued sales growth demonstrates the strategic importance of Craneware and its Value Cycle solutions to them as they meet these challenges. The ongoing investment we are making to develop solutions that discover, convert and optimise value for healthcare providers, combined with our own historical sales successes, double digit revenue and adjusted EBITDA growth, give management confidence in its ability to deliver continued future growth as well as increasing stakeholder value."



The Company will announce its Full Year Results on 6 September 2016.

6 Jul Peel Hunt 920.00 Buy

Craneware PLC (CRW:LSE) set a new 52-week high during Wednesday's trading session when it reached 895.00. Over this period, the share price is up 44.44%.

25 Aug Peel Hunt 1,335.00 Buy

Final Results

RNS


RNS Number : 0121J

Craneware plc

06 September 2016




Craneware plc

("Craneware", "the Group" or the "Company")

Final Results



6 September 2016 - Craneware plc (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, announces its results for the year ended 30 June 2016.



Financial Highlights (US dollars)
•Total Contract Value in the year continues at record levels of $82.3m (FY15: $72.9m) ◦new sales increased by 63% to $58.6m (FY15: $35.9m)
◦renewal rate remains above 100% by dollar value

•Revenue increased 11% to $49.8m (FY15: $44.8m)
•Adjusted EBITDA1. increased by 10% to $15.9m (FY15: $14.4m)
•Profit before tax increased by 10% to $13.9m (FY15: $12.5m)
•Basic adjusted EPS increased 13% to $0.429 (FY15: $0.378) and adjusted diluted EPS has increased to $0.423 (FY15: $0.375)
•Continued operating cash conversion above 100% of Adjusted EBITDA
•Cash at year-end of $48.8m (FY15: $41.8m) after payment of $6m dividend to shareholders
•Proposed final dividend of 9p (12 cents) per share giving a total dividend for the year of 16.5p (22 cents) per share (FY15: 14p (22 cents) per share)



1. Adjusted EBITDA refers to earnings before acquisition and share related transaction costs, interest, tax, depreciation, amortisation and share based payments.





Operational Highlights (Finals)
•US healthcare market continues its evolution towards value-based care with a critical dependency on accurate financial and operating data
•Further expansion of the product suite to support the Value Cycle, including: ◦development of Trisus Patient Payment Module, our Patient Engagement and Access gateway product, on track for launch during calendar 2016
◦launch of Craneware Healthcare Intelligence, a new group business, developing new solutions to address an emerging but significant market opportunity for healthcare cost analytics

•Two significant 5 year contract wins in the year for Craneware core value cycle solutions, worth a combined $15.5m
•Continued very high levels of customer retention
•Total visible revenue increased 23% to $149.1m (FY15 same 3 year period: $121.1m)



Keith Neilson, CEO of Craneware plc commented, "Craneware is in a stronger position than ever and we are passionate about the opportunity ahead. The double digit growth in our reported revenue and adjusted EBITDA are only beginning to reflect the record levels of sales which began three years ago. Importantly, the investment we are making in our product suite mean our market opportunity is now several times larger than it was when we joined AIM in 2007.



"The market continues to evolve as we anticipated. US healthcare providers are seeking the solutions to address the challenges the new value based re-imbursement environment brings to them. We believe the investment we are making to expand the products in our Value Cycle suite addresses these challenges and we are now recognised beyond our original niche within the revenue cycle as a more strategic provider within a hospital's financial operations and their value cycle.



"We are confident that the ongoing investment we are making, combined with our continuing sales successes, mean we are well positioned to deliver continued future growth as well as increasing stakeholder value."

New high.

Director/PDMR Shareholding
RNS
RNS Number : 2394K
Craneware plc
20 September 2016
 
 
Craneware plc
("Craneware" or the "Company")
 
Director Shareholding
 
20 September 2016 - Craneware plc (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, has been informed that Keith Neilson, CEO of the Company, yesterday purchased 5,388 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 1,200 pence per share.
 
Following this transaction, Mr. Neilson's beneficial interest in Craneware has increased to 3,509,518 Ordinary Shares, representing approximately 13.1% of the Company's issued Ordinary Share capital.
 

AGM Statement
RNS
RNS Number : 5525O
Craneware plc
08 November 2016
 
Craneware plc
("Craneware", "the Group" or the "Company")
AGM Statement
 
8 November 2016 - Craneware plc (AIM: CRW.L), the leader in Value Cycle solutions for the US healthcare market, will be holding its Annual General Meeting today at 10am. At the meeting, Keith Neilson, CEO of the Company, will make the following statement:
 
"We continue to see positive results in the first few months of the current fiscal year. In September we announced the move back into double-digit revenue and adjusted EBITDA growth. With the impact of sales made during FY16 starting to contribute to revenue, combined with our sales pipeline and activity, we see that momentum continuing in the current year.
 
"The US healthcare market continues its evolution towards value-based care with a critical dependency on accurate financial and operating data. We are investing in our Value Cycle product suite to ensure we have the solutions to provide hospitals with tools that deliver insight into these areas of their operations, expanding our market opportunity and increasing our strategic value within our market.
 
"2017 will see some exciting developments for Craneware with the launch of Trisus Claims Informatics, the first product to be launched on our newly developed cloud-based Trisus Enterprise Value Platform; followed shortly thereafter by the launch of Trisus Patient Payment, a new fourth gateway product, operating within the patient access and engagement area. 
 
"We are also making good progress within our newly formed Group business, Craneware Healthcare Intelligence, which is focused on the development of cost analytics software for the US healthcare industry.
 
"With our expanded offering and market opportunity, high levels of revenue visibility and favourable market backdrop, we believe we are just at the start of a long-term growth trajectory and are confident in the future success of Craneware."